NCT05775718View on ClinicalTrials.gov

Shingrix In Recipients of Allogeneic Transplants

PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2030

Conditions
Bone Marrow TransplantStem Cell Transplant
Interventions
DRUG

Zoster Vaccine Recombinant

Injection

Trial Locations (1)

80045

RECRUITING

University of Colorado Hospital, Aurora

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Colorado, Denver

OTHER

NCT05775718 - Shingrix In Recipients of Allogeneic Transplants | Biotech Hunter | Biotech Hunter